REC-1 cells could therefore represent a class of MCL cells that in a clinical context would be refractory to Ibrutinib and other BTK inhibitors that are now being used clinically even though, like REC-1, such cells might have a functional BCR system. This evidence concerns the gene BTK and mantle cell lymphoma.